A recent study indicates that abnormal upregulation of NRF2 leads to metabolic reprogramming and subsequent chemoresistance to cancer therapies- a finding that underscores the clinical relevance of NRF2 in cellular metabolism [48]. Here, NFE2L2 is linked to cancer.